Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GNLX | GENELUX Corp | 2026-04-02 18:53:31 | 2.41 | -0.16 | -6.28 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNLX | 0001231457 | GENELUX Corp | US36870H1032 | — | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 2625 TOWNSGATE ROAD, SUITE 230 | WESTLAKE VILLAGE | CA | 91361 | UNITED STATES | US | 805-267-9889 | 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361 | 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361 | — | Biopharmaceuticals | 2001 | — | — | http://genelux.com | 89,100,000 | 38,139,144 | 44,805,811 | Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. | 2026-04-02 19:16:55 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 89,100,000 | 31,200,000 | 53.886 | 44,805,811 | 7,070,844 | 18.7382 |
| 2024 | 57,900,000 | -613,400,000 | -91.3749 | 37,734,967 | 10,869,494 | 40.459 |
| 2023 | 671,300,000 | 671,300,000 | 100 | 26,865,473 | 26,865,473 | 100 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Joseph Cappello, Ph.D. | Chief Technical Officer | 2024 | 360,000 | — | 166,678 | — | 3,048 | 601,814 |
| Lourie Zak | Chief Financial Officer | 2024 | 360,000 | — | 128,953 | — | 1,584 | 595,018 |
| Thomas D. Zindrick, J.D. | Chief Executive Officer, President | 2024 | 595,000 | — | 536,942 | — | 3,048 | 1,473,247 |
| Lourie Zak | Chief Financial Officer | 2023 | 119,077 | — | 0 | — | 157 | 2,830,362 |
| Thomas D. Zindrick, J.D. | Chief Executive Officer, President | 2023 | 570,519 | — | 151,110 | — | 471 | 6,201,963 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 25 |
| 2024 | 24 |
| 2023 | 23 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 8,000 | 8,000 | 170,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 19,851,000 | 18,998,000 | 12,767,000 |
| General And Administrative Expenses | 13,371,000 | 12,706,000 | 11,568,000 |
| Operating Expenses | 33,222,000 | 31,704,000 | 24,335,000 |
| Operating Income | -33,214,000 | -31,696,000 | -24,165,000 |
| Net Income | -32,145,000 | -29,869,000 | -28,297,000 |
| Earnings Per Share Basic | -0.86 | -0.95 | -1.16 |
| Earnings Per Share Diluted | -0.86 | -0.95 | -1.16 |
| Weighted Average Shares Outstanding Basic | 37,176,527 | 31,450,727 | 24,429,278 |
| Weighted Average Shares Outstanding Diluted | 37,176,527 | 31,450,727 | 24,429,278 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 5,333,000 | 8,565,000 | 9,418,000 |
| Marketable Securities Current | — | 22,330,000 | 13,773,000 |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 15,130,000 | 31,548,000 | 24,203,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 2,170,000 | 1,316,000 | 1,170,000 |
| Other Assets Non Current | 144,000 | 92,000 | 92,000 |
| Total Assets Non Current | 3,897,000 | 3,168,000 | 3,690,000 |
| Total Assets | 19,027,000 | 34,716,000 | 27,893,000 |
| Accounts Payable | 4,358,000 | 5,570,000 | 3,784,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | 900,000 |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 6,225,000 | 6,903,000 | 6,554,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 1,258,000 | 1,539,000 | 1,866,000 |
| Total Liabilities | 7,483,000 | 8,442,000 | 8,420,000 |
| Common Stock | 38,000 | 35,000 | 27,000 |
| Retained Earnings | -283,538,000 | -251,393,000 | -221,524,000 |
| Accumulated Other Comprehensive Income | 9,000 | 64,000 | 14,000 |
| Total Shareholders Equity | 11,544,000 | 26,274,000 | 19,473,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 244,000 | 235,000 | 499,000 |
| Share Based Compensation Expense | 5,871,000 | 5,738,000 | 2,515,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -1,213,000 | 2,156,000 | -2,358,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -25,268,000 | -21,228,000 | -20,275,000 |
| Purchases Of Marketable Securities | 18,261,000 | 29,000,000 | 13,699,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 1,098,000 | 381,000 | 1,025,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 12,141,000 | -8,131,000 | -14,724,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 9,553,000 | — | 25,142,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 9,895,000 | 28,506,000 | 44,020,000 |
| Change In Cash | -3,232,000 | -853,000 | 9,021,000 |
| Cash At End Of Period | 5,333,000 | 8,565,000 | 9,418,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | 72,000 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Earnings Per Share | -0.86 | -0.95 |
| Price To Earnings Ratio | -5.0698 | -2.4842 |
| Earnings Growth Rate | -9.4737 | -18.1034 |
| Price Earnings To Growth Ratio | 0.5351 | 0.1372 |
| Book Value Per Share | 0.3105 | 0.8354 |
| Price To Book Ratio | 14.041 | 2.825 |
| Ebitda | -31,901,000 | -29,634,000 |
| Enterprise Value | — | — |
| Dividend Yield | — | — |
| Dividend Payout Ratio | — | — |
| Debt To Equity Ratio | — | — |
| Capital Expenditures | 1,098,000 | 381,000 |
| Free Cash Flow | -26,366,000 | -21,609,000 |
| Return On Equity | -2.7846 | -1.1368 |
| One Year Beta | 1.2855 | 1.4711 |
| Three Year Beta | 1.3694 | 1.4798 |
| Five Year Beta | 1.3694 | 1.4798 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Smalling Ralph | Head of Regulatory | 2026-03-25 | 240 | D | 68,073 |
| Zindrick Thomas | President and CEO | 2026-03-24 | 3,582 | D | 534,849 |
| Yu Yong | SVP, Clinical Development | 2026-03-24 | 906 | D | 144,938 |
| Cappello Joseph | Chief Technical Officer | 2026-03-24 | 906 | D | 155,154 |
| Smalling Ralph | Head of Regulatory | 2026-03-24 | 345 | D | 68,313 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 801,398 | 183,807 | 4.36 |
| RAYMOND JAMES FINANCIAL INC | 2025-12-31 | 134,105 | 30,758 | 4.36 |
| Point72 Asset Management, L.P. | 2025-12-31 | 172,482 | 39,560 | 4.36 |
| CITADEL ADVISORS LLC | 2025-12-31 | 84,649 | 19,415 | 4.36 |
| MILLENNIUM MANAGEMENT LLC | 2025-12-31 | 455,180 | 104,399 | 4.36 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Dimensional ETF Trust | 2026-01-31 | Dimensional U.S. Core Equity 2 ETF | DFAC | 3,647 | 9,701.02 | 0.0 |
| VICTORY PORTFOLIOS III | 2026-01-31 | Victory Extended Market Index Fund | USMIX | 3,259 | 8,668.94 | 0.0011 |
| Advisors' Inner Circle Fund III | 2026-01-31 | I Shares | KCXIX | 165 | 438.9 | 0.0001 |
| SCHWAB CAPITAL TRUST | 2026-01-31 | Schwab Total Stock Market Index Fund | SWTSX | 25,000 | 66,500 | 0.0002 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 2025-12-31 | Institutional Plus Shares | VITPX | 16,729 | 72,938.44 | 0.0002 |